Sort
78,016 grants matching “breast cancer”
Molecular Analysis of Breast Cancer Metastasis to the Brain
$1,185,798Patricia Schriver Steeg · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
COHORT STUDY OF DIETARY SUPPLEMENTS AND CANCER RISK
$1,185,785Fred Hutchinson Cancer Research Center · R01 · FY2002 · CA
Anti-carcinogenic Activity Of Cox inhibitors and NAG-1
$1,185,009Thomas Eling · National Institute Of Environmental Health Sciences · ZIA · FY2012 · ES
HARNESSING DRUGGABLE SYNTHETIC LETHAL INTERACTIONS IN TRIPLE-NEGATIVE BREAST CANCER WITH ELEVATED MYC EXPRESSION
$1,185,000Northwestern University · · FY2018 · Department of the Army
National Cooperative Drug Discovery Groups for Cancer
$1,184,968University Of California Santa Cruz · U19 · FY2005 · CA
TRANSLATIONAL SIGNIFICANCE OF P53 LOSS OF HETEROZYGOSITY IN BREAST CANCER
$1,184,836The Research Foundation For The State University Of New York · · FY2016 · Department of the Army
CCR Genomics Core
$1,184,368Elizabeth Conner · Division Of Basic Sciences - Nci · ZIC · FY2017 · CA
A PEPTIDE THERAPEUTIC FOR SUPPRESSING BREAST CANCER METASTASIS
$1,184,010Rockefeller University · · FY2014 · Department of Defense
GENE EXPRESSION IN CANCER BY MICROARRAY HYBRIDIZATION
$1,183,865Stanford University · R01 · FY2004 · CA
PLCO Trial Etiologic and Early Marker Study
$1,182,573Steven Moore · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA
Enhancing Native American Participation in RT Trials
$1,182,097Daniel G Petereit · Rapid City Regional Hospital · U56 · FY2006 · CA
IDENTIFY AND TARGET INNATE IMMUNE CHECKPOINTS TO TREAT METASTATIC BREAST CANCER
$1,181,609The Leland Stanford Junior University · · FY2018 · Department of the Army
A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients
$1,181,406Stephanie Deshayes · Tempo Therapeutics, Inc. · R44 · FY2022 · DK
ROLE OF BONE-DERIVED TGF-BETA IN GLUCOSE METABOLISM IN THE SETTING OF BREAST CANCER BONE METASTASES
$1,181,250The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2018 · Defense Health Agency
Clinical Proteomic Technology Assessment for Cancer
$1,181,217Daniel C Liebler · Vanderbilt University · U24 · FY2009 · CA
COBRE Center for Cancer Research Development
$1,181,126Bharat Ramratnam · Rhode Island Hospital · P30 · FY2016 · GM
VCU Massey Cancer Center Minority/Underserved NCI Community Oncology Research Program
$1,180,709Khalid Matin · Virginia Commonwealth University · UG1 · FY2022 · CA
ENHANCING PRECISION ONCOLOGY FOR UNDERSERVED BREAST CANCER PATIENTS THROUGH DEEP LEARNING-AIDED HISTOPATHOLOGY ANALYSIS
$1,180,294The General Hospital Corporation · · FY2025 · Defense Health Agency
METROPOLITAN NEW YORK REGISTRY OF BREAST CANCER FAMILIES
$1,180,170Columbia University Health Sciences · U01 · FY2003 · CA
Molecular and Functional Characterization of Colon Tumor Cancer Stem Cells and St
$1,180,000Michael Clarke · Stanford University · U54 · FY2006 · CA
General Studies of Epidemiology
$1,179,864Robert Hoover · Division Of Cancer Epidemiology And Genetics · ZIA · FY2009 · CA
IMMUNE CONTROL OF TRIPLE-NEGATIVE BREAST CANCER BY WEE1 INHIBITION
$1,179,661Northwestern University · · FY2019 · Department of the Army
Essentia Health Community Cancer Research Program - NCORP
$1,179,310Bret E.b. Friday · Essentia Institute Of Rural Health · UG1 · FY2023 · CA
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
$1,178,924Thomas E Rohan · Albert Einstein College Of Medicine · R01 · FY2019 · CA
Multiscale Mathematical Modeling of Cancer Progression
$1,178,908Vito Quaranta · Vanderbilt University · U54 · FY2014 · CA